Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack
NCT ID: NCT00399503
Last Updated: 2016-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
350 participants
OBSERVATIONAL
2001-09-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Myocardial Infarction Quality Assurance Project
NCT02399891
Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation
NCT03345615
Heart Rate Variability as a Predictor of Ischemic Heart Disease
NCT02959788
T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy
NCT00589849
Ventricular Remodeling and Heart Failure After Myocardial Infarction: a Community Study
NCT02047396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Given the grave consequences of SCD, an ideal testing procedure should identify most of those at risk (sensitive) \& correctly classify risk (accurate). Since \>90% of patients who suffer serious arrhythmias post-MI have at least mild left ventricular (LV) dysfunction (ejection fraction \[EF\] \<0.50) this is an optimal group to study.
While noninvasive tests have been developed to estimate SCD risk, prior approaches have failed to: 1) identify the majority of patients at risk for serious arrhythmias (insensitive), 2) evaluate temporal changes in parameters, 3) identify the optimal timing for risk assessment post-MI, \& 4) develop a widely-applicable screening tool. This has resulted in a failure to delivery effective therapies (e.g., defibrillator) in a cost-effective manner.
Hypotheses. Primary: Concurrent evaluation of electrical structure \& autonomic tone will accurately identify most post-MI patients at risk of serious arrhythmic events. Secondary: 1) assessment later (16 weeks) provides more prognostic information than assessment early post-MI (4 weeks), 2) a single multi-parameter test procedure can be developed, and 3) individually, repolarization alternans provides the most prognostic information.
Methods. 350 persons with a recent MI (\<31 days) \& EF \<0.50 will undergo testing early (4 weeks), intermediate (8 weeks) \& late (16 weeks) post-MI.
Four techniques assess cardiac structure (spectral T-wave alternans \[TWA\], modified moving average TWA; signal-averaged \[SA\] ECG) \& nuclear ejection fraction. Three others evaluate autonomic tone (baroreceptor sensitivity \[BRS\], heart rate variability \[HRV\], and Heart Rate Turbulence \[HRT\]).
Data Collection \& Outcomes. Patients will be recruited over 24 months \& followed biannually for four years. Committee (blinded) endpoint classification \& central laboratory data analysis will be utilized. A composite of resuscitated cardiac arrest and cardiac mortality is the primary outcome. The components (resuscitated / non-resuscitated cardiac arrest and cardiac death) are secondary outcomes.
Statistical Aspects \& Sample Size. Standard methods of description \& analysis will be used. The capacity to accurately identify most patients at risk for serious arrhythmias will be evaluated using Cox multivariate models. The primary model will include age, sex, EF at 8 wks \& important baseline medication use.
Since multivariate modeling requires lower (more sensitive) dichotomy limits the following will be used: spectral TWA positivity will be defined as a non-negative test. SA-ECG QRS width \>104 msec will be labeled as abnormal. For HRV, SDNN values \<105 msec will be considered abnormal. For BRS, values \<6.1 msec per mmHg will indicate impairment. For HRT abnormalities in T-onset \& / or T-slope will be considered abnormal. Receiver operating characteristic curves will be used to identify a cut-point for modified moving average TWA.
Assuming a 5 year 20% rate of the composite arrhythmias in patients with positive test results, we have 85% power to detect a 2.5-fold higher risk in patients with abnormalities than those without these abnormalities.
Relevance. This is the first large prospective study to evaluate the utility of concurrent structural \& autonomic tone assessment in predicting the development of serious arrhythmias after an MI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spectral T Wave Alternans
Modified Moving Average T Wave Alternans
Baroreceptor Sensitivity
Heart Rate Variability
Heart Rate Turbulence
Deceleration Capacity
Signal Averaged ECG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical symptoms or ECG evidence of myocardial injury (ST deviation ≥ 1 mm in 2, contiguous leads or new/previously undocumented Q waves)144, \&
* left ventricular ejection fraction ≤ 0.40 within 48 hrs or ≤ 0.50 beyond 48 hrs of MI using (echocardiography, radionuclide or contrast angiography) \&
* Sinus rhythm at the time of enrollment.
Exclusion Criteria
* Comorbid illness likely to cause death within 24 months,
* Inability to complete a submaximal exercise test (e.g., urgent CABG),
* Class I indication for a defibrillator (e.g., VF or sustained VT \> 48 hours of index MI), or
* Lack of written informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Heart and Stroke Foundation of Canada
OTHER
Alberta Heritage Foundation for Medical Research
OTHER
GE Healthcare
INDUSTRY
Cambridge Heart Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY
University of Calgary
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Derek V Exner, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Libin Cardiovascular Institute of Alberta, University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foothills Hospital
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007 Dec 11;50(24):2275-84. doi: 10.1016/j.jacc.2007.08.042. Epub 2007 Nov 26.
Slawnych MP, Nieminen T, Kahonen M, Kavanagh KM, Lehtimaki T, Ramadan D, Viik J, Aggarwal SG, Lehtinen R, Ellis L, Nikus K, Exner DV; REFINE (Risk Estimation Following Infarction Noninvasive Evaluation); FINCAVAS (Finnish Cardiovascular Study) Investigators. Post-exercise assessment of cardiac repolarization alternans in patients with coronary artery disease using the modified moving average method. J Am Coll Cardiol. 2009 Mar 31;53(13):1130-7. doi: 10.1016/j.jacc.2008.12.026.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSFA 73-1220
Identifier Type: -
Identifier Source: secondary_id
CIHR 73-1518
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.